RxDoctor Payments DataLook up a doctor →

Mark Silverman, DO

Neurology · Farmington Hills, MINPI 1336147958

Payments from drug & device makers

$225,488in general payments, 2019–2025

Across 1,869 payments — averaging $120.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$122K
  • Sanofi$44K
  • EMD Serono, Inc.$19K
  • E.r. Squibb & Sons, L.L.C.$13K
  • Bristol Myers Squibb$9K
  • Novartis$2K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$31,56814%
  • Speaking & faculty fees$146,99565%
  • Travel & lodging$12,0495%
  • Food & beverage$34,83815%
  • Education$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen256$121,678
Sanofi140$43,604
EMD Serono, Inc.167$18,538
E.r. Squibb & Sons, L.L.C.24$12,673
Bristol Myers Squibb131$9,065
Novartis227$2,455
Teva Pharmaceuticals USA, Inc.106$1,512
AbbVie(2 entities)99$1,499
UCB, Inc.77$1,428
Neurocrine Biosciences, Inc.45$970
TG Therapeutics, Inc.35$957
CSL Behring47$836
Eisai Inc.27$711
Amgen(2 entities)38$704
Johnson & Johnson(2 entities)29$666
Takeda Pharmaceuticals U.S.A., Inc.27$590
AstraZeneca(2 entities)30$563
Acadia Pharmaceuticals Inc29$501
Lundbeck LLC16$429
Genentech USA, Inc.20$364
Lilly USA, LLC19$361
MDD US Operations, LLC21$343
Sumitomo Pharma America, Inc.19$325
Vanda Pharmaceuticals Inc.13$287
SK Life Science, Inc.11$265
Avanir Pharmaceuticals, Inc.10$265
Kyowa Kirin, Inc.12$226
Neurelis, Inc.9$226
Acorda Therapeutics, Inc11$225
Catalyst Pharmaceuticals, Inc.6$213
Adamas Pharmaceuticals, Inc.12$209
Grifols USA, LLC12$196
Pfizer11$180
Alnylam Pharmaceuticals Inc.10$170
Boston Scientific2$165
Corium, LLC10$149
Merz Pharmaceuticals, LLC4$130
Jazz Pharmaceuticals Inc.7$125
Octapharma USA, Inc.4$105
Argenx US, Inc.5$103
Sunovion Pharmaceuticals Inc.8$99
Banner Life Sciences, LLC6$96
Aucta Pharmaceuticals, Inc.8$94
Livanova USA, Inc.5$88
Biohaven Pharmaceuticals, Inc.6$84
Biohaven Pharmaceutical Holding Company Ltd.4$81
Akcea Therapeutics, Inc.5$77
Upsher-smith Laboratories LLC4$77
Supernus Pharmaceuticals, Inc.5$74
Zogenix Inc.4$66
Otsuka America Pharmaceutical, Inc.4$62
Cycle Pharmaceuticals Inc3$58
Tanabe Pharma America, Inc.3$52
Xeris Pharmaceuticals, Inc.3$51
Amneal Pharmaceuticals LLC2$46
Cala Health, Inc.3$43
Bausch Health US, LLC2$40
ANI Pharmaceuticals, Inc.2$40
Mallinckrodt Hospital Products Inc.2$39
Hospira, Inc.2$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,488 in reported general payments places this provider in the 90th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$282,546
Medicare patients
564
Services billed
2,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZeposiaOzanimod Hydrochloride17$229,788
AubagioTeriflunomide16$208,594
IngrezzaValbenazine Tosylate23$193,346
AustedoDeutetrabenazine27$192,522
Kesimpta PenOfatumumab12$189,821
VumerityDiroximel Fumarate18$154,950
Avonex (4 Pack)Interferon Beta-1a13$100,579
Aimovig AutoinjectorErenumab-Aooe20$32,696
Teriflunomide12$30,750
VimpatLacosamide14$20,821
NeuproRotigotine13$16,182
Dalfampridine ErDalfampridine26$14,146
AptiomEslicarbazepine Acetate11$12,800
FingolimodFingolimod Hcl15$12,440
Galantamine ErGalantamine Hbr93$11,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Avonex (4 Pack)$121,678$255,52831 claims
E.r. Squibb & Sons, L.L.C.Zeposia$12,673$229,78817 claims
SanofiAubagio$43,604$208,59416 claims
Neurocrine Biosciences, Inc.Ingrezza$970$193,34623 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,512$192,52227 claims
UCB, Inc.Vimpat, Neupro$1,428$37,00427 claims
Sunovion Pharmaceuticals Inc.Aptiom$99$12,80011 claims
PfizerDilantin$180$2,59912 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$46$2,52412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 neurology providers in Michigan.

Other neurology in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →